Teva is down -8.7%, or -81c to $8.46.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA:
- Teva discloses FDA Complete Response Letter to partner Alvotech for AVT02
- Teva call volume above normal and directionally bullish
- Teva’s CP trial failure may add some risk for Neurocrine, says RBC Capital
- Teva and NATCO Pharma launch additional strengths for generic Revlimid
- Teva announces print publication of IMPACT-TD Scale